2026 NPPES data Endocrinology, Diabetes & Metabolism Physician NPI 1043637192 D.O
Verify on CMS →

FADWA SUMREIN, D.O

Endocrinology, Diabetes & Metabolism Physician in CLIFTON, New Jersey. CMS National Plan and Provider Enumeration System profile including specialty classification, practice address, and Medicare prescribing data when reported.

Federal data — no proprietary rating. PlainDoctor publishes the actual CMS NPPES and Medicare records — NPI registration, specialty, practice location, and prescribing data — without a composite score or editorial opinion on top. Every field traces to a federal source.
Prescribing volume
7K
Medicare Part D claims · 604 beneficiaries · Endocrinology, Diabetes & Metabolism Physician avg: 3K
Generic prescribing
38%
generic claims · 62% brand-name · higher generic rates reduce patient out-of-pocket costs
MIPS score
94.9574/100
▲ 12 pts above national avg 83.1 · [object Object]
Industry payments
$2.2K
65 payments · CMS Open Payments (Sunshine Act)

What the federal data shows

FADWA SUMREIN, D.O reported a CMS MIPS final score of 94.9574/100 — above the 83.1 national average — and filed 6,559 Medicare Part D claims in 2023.

94.9574/100
MIPS score · +12 vs avg
7K
Part D claims, 2023
38%
generic prescribing
Likely
board-certified (heuristic)

Every figure on this page comes straight from federal CMS records (NPPES, Medicare Part D, MIPS, Open Payments) — no proprietary rating or editorial opinion is applied.

FADWA SUMREIN, D.O's MIPS score vs every scored U.S. clinician

CMS Merit-based Incentive Payment System (MIPS) final score, 2023 — the federal quality measure

95 Top 25% higher than 75% of 477,587 scored providers

0–10: 8,684 scored providers (2%). Below this entry. 10–20: 3,008 scored providers (1%). Below this entry. 20–30: 3,069 scored providers (1%). Below this entry. 30–40: 2,746 scored providers (1%). Below this entry. 40–50: 2,928 scored providers (1%). Below this entry. 50–60: 5,882 scored providers (1%). Below this entry. 60–70: 13,906 scored providers (3%). Below this entry. 70–80: 118,074 scored providers (25%). Below this entry. 80–90: 129,887 scored providers (27%). Below this entry. 90–100: 189,403 scored providers (40%). This entry sits in this band. This provider 0 100 every MIPS-scored clinician, bucketed by value

Each bar is a band; taller bars hold more scored providers. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source CMS Merit-based Incentive Payment System (MIPS) · 2023

Board certification likely (heuristic — not verified)

FADWA SUMREIN, D.O practices in an ABMS-board-eligible specialty and shows active CMS Medicare participation + MIPS quality reporting + 1 hospital affiliation — signals consistent with board-certified status. For verified board certification, see CertificationMatters.org (the official ABMS public lookup).

What does the federal data show about FADWA SUMREIN, D.O?

High performer (top quartile)

NPI registry status

Active

Issued 03/26/2014

NPI 1043637192

Primary specialty

Endocrinology, Diabetes & Metabolism Physician

Mid-sized

7,852 US NPIs in this specialty

Medicare Part D claims

6,559 149% vs specialty avg

2023 prescription claims

Specialty avg: 2,639

MIPS final score

94.9574/100 11.857400000000013% pts

Exceptional band

vs 83.1 national avg

Specialty distribution in New Jersey

How Endocrinology, Diabetes & Metabolism Physician compares to other specialties among New Jersey providers

New Jersey providers

Endocrinology, Diabetes & Metabolism Physician share within New Jersey

1. Endocrinology, Diabetes & Metabolism Physician42%2. Internal medicine21%3. Family medicine17%4. Surgical12%5. Pediatric8%
Endocrinology, Diabetes & Metabolism Physician share within New Jersey

Medicare quality performance — MIPS

FADWA SUMREIN, D.O's 2023 MIPS final score plotted against the Endocrinology, Diabetes & Metabolism Physician national average

High performer (top quartile)
MIPS Final Score
94.9574/100
vs 83.1 national avg · 2023 performance year

MIPS final score (Endocrinology, Diabetes & Metabolism Physician) — 94.9574/100 vs national avg 83.1

0%100%National avg83%95%
MIPS final score (Endocrinology, Diabetes & Metabolism Physician) — 94.9574/100 vs national avg 83.1

The Merit-based Incentive Payment System (MIPS) scores providers 0–100 across four performance categories: Quality, Cost, Promoting Interoperability, and Improvement Activities, weighted under 42 CFR §414.1380. Reporting is voluntary for many small practices, so absence of a MIPS score is not a quality signal.

Board certification through an ABMS or AOA member board signals voluntary post-licensure examination plus continuous Maintenance of Certification cycles. Verify any individual provider's status through certificationmatters.org (ABMS) or osteopathic.org (AOA).

FADWA SUMREIN, D.O appears in the CMS NPPES registry as a Endocrinology, Diabetes & Metabolism Physician provider holding D.O credentials at 2 BRIGHTON RD STE 400, CLIFTON, NJ, 07012, with a listed phone of (862) 297-9696. NPI 1043637192 was issued on 03/26/2014. Because NPPES data is self-reported by the provider and refreshed monthly, the address, phone, and specialty reflect what SUMREIN most recently submitted to CMS rather than a vetted directory listing, which is why patients should always confirm the practice is still at this location before scheduling.

Medicare Part D records for calendar year 2023 show 6,559 prescription claims written by this provider, covering 604 Medicare beneficiaries and totaling roughly $4.3 million in drug spend, split 62% brand-name and 38% generic by claim count. These figures capture only Medicare Part D — commercial insurance, Medicaid, and cash-pay prescriptions are not included, and any drug-beneficiary cell under 11 is suppressed by CMS for patient privacy. On the CMS Merit-based Incentive Payment System, this provider earned a Final Score of 94.9574/100 for the 2023 performance year (Quality 87.2651), compared with the national average of 83.1.

Endocrinology, Diabetes & Metabolism Physician is a mid-sized specialty nationwide, with 7,852 enrolled providers across 54 states and an average of 2,639 Part D claims per prescriber, so the context for interpreting these metrics differs meaningfully from a primary-care baseline. Important: PlainDoctor is a directory of publicly available government data, not medical advice, a malpractice database, or a quality rating. Inclusion here does not imply a recommendation, and absence of complaints or sanctions on this page does not mean none exist — always verify credentials through the NPPES NPI Registry, your state medical board, and the ABMS or AOA before making healthcare decisions.

Practice Address

2 BRIGHTON RD STE 400
CLIFTON, NJ 07012

Provider Details

NPI 1043637192
Specialty Endocrinology, Diabetes & Metabolism Physician
Credentials D.O
Gender Female
NPI Issued 03/26/2014

CMS Quality Score (MIPS)

Merit-based Incentive Payment System (MIPS) scores from CMS, 2023 performance year.

94.9574
Final Score
Avg: 83.1
87.2651
Quality
100
Promoting Interoperability

Reporting: Alternative Payment Model

Hospital and facility affiliations

Facilities where FADWA SUMREIN, D.O bills Medicare from. Star ratings (1-5) are CMS Hospital Compare's "Hospital overall rating" — a composite of mortality, readmission, patient experience, safety, timely care, and efficient use of medical imaging measures. Source: CMS Care Compare.

MEDICAL ASSOCIATES OF ENGLEWOOD PC
CLIFTON, NJ

Affiliations sourced from CMS Doctors and Clinicians National Downloadable File; hospital ratings from CMS Hospital General Information dataset (cross-referenced by facility name + state).

Industry payments received (2024) — CMS Open Payments transparency data

The federal Physician Payments Sunshine Act (part of the Affordable Care Act) requires drug and medical-device manufacturers + group purchasing organizations to publicly report payments and other transfers of value to physicians and teaching hospitals. The data below covers 2024 for FADWA SUMREIN, D.O. Source: openpaymentsdata.cms.gov.

Total received

$2.2K

Largest payer

Medtronic, Inc.

Most common payment type

Food and Beverage

Industry payments are not necessarily indicators of bias — they include research funding, consulting fees for evidence-based work, royalties for inventions, food at conferences, and similar items. The disclosure exists for transparency. Read our methodology for how we interpret this data.

Brand vs generic prescribing mix · Brand-heavy

FADWA SUMREIN, D.O — brand share 62.0%
Specialty average (est.)

62% brand-name claims vs 38% generic, on 6,559 2023 Medicare Part D claims.

The federal Medicare Part D Generic Dispensing Rate national benchmark sits near 90% generic / 10% brand for primary-care prescribers, per CMS Office of the Actuary 2024 estimates. Higher brand share is common in specialty prescribing where generic equivalents are not available.

Medicare Part D Prescribing Data

CMS Medicare Part D prescriber-level data for calendar year 2023.

6,559
Total Claims
$4.3M
Total Drug Cost
604
Medicare Beneficiaries

Prescribing Breakdown

30-Day Fills
12,236
Total Day Supply
361,037
Brand vs Generic
62% brand / 38% generic
Brand Drug Cost
$4.0M
Generic Drug Cost
$171K

Patient Demographics

Average Patient Age
69.4 years
Avg HCC Risk Score
2.01
Gender Split
64% female / 36% male
Age Distribution
<65: 140, 65-74: 282, 75-84: 144, 85+: 38

Top Prescribed Drugs (Medicare Part D)

Top drugs by claim count for calendar year 2023. Based on Medicare Part D data only.

What FADWA SUMREIN, D.O prescribes most

Top Medicare Part D drugs by claim count, 2023

claims
Source CMS Medicare Part D Prescriber Public Use File As of 2023
Drug Claims
Ozempic
Semaglutide
777
Trulicity
Dulaglutide
636
Jardiance
Empagliflozin
584
Metformin Hcl
517
Levothyroxine Sodium
340
Farxiga
Dapagliflozin Propanediol
305
Humalog Kwikpen U-100
Insulin Lispro
146
Repaglinide
133
Atorvastatin Calcium
132
Synjardy Xr
Empagliflozin/Metformin Hcl
90

* Counts below 11 are suppressed by CMS for patient privacy. Generic names shown where available from CMS Part D data.

Endocrinology, Diabetes & Metabolism Physician Overview

How FADWA SUMREIN, D.O fits within the Endocrinology, Diabetes & Metabolism Physician landscape nationally.

7,852
Endocrinology, Diabetes & Metabolism Physician Providers in US
54
States with Endocrinology, Diabetes & Metabolism Physician
2,639
Avg Claims per Provider

FADWA SUMREIN, D.O's 6,559 claims are above the specialty average of 2,639.

Nearby Endocrinology, Diabetes & Metabolism Physician Providers in New Jersey

Other clinicians with the same primary specialty enrolled in New Jersey, drawn from the same CMS NPPES roster as SUMREIN.

Compare Endocrinology, Diabetes & Metabolism Physician nationally: see state-by-state distribution →

Frequently Asked Questions

What is FADWA SUMREIN, D.O's specialty?
FADWA SUMREIN, D.O specializes in Endocrinology, Diabetes & Metabolism Physician and practices in CLIFTON, New Jersey. Credentials: D.O.
How much does FADWA SUMREIN, D.O prescribe under Medicare Part D?
In 2023, FADWA SUMREIN, D.O wrote 6,559 Medicare Part D claims totaling $4.3M in drug costs for 604 beneficiaries.
What is FADWA SUMREIN, D.O's Medicare quality score?
FADWA SUMREIN, D.O has a CMS MIPS Final Score of 94.9574/100 (Quality: 87.2651). The national average MIPS Final Score is 83.1. Source: CMS Merit-based Incentive Payment System (MIPS) 2023.
Where is FADWA SUMREIN, D.O located?
FADWA SUMREIN, D.O is located at 2 BRIGHTON RD STE 400, CLIFTON, NJ, 07012. Phone: (862) 297-9696.
What is FADWA SUMREIN, D.O's NPI number?
FADWA SUMREIN, D.O's National Provider Identifier (NPI) is 1043637192, issued on 03/26/2014.
Does FADWA SUMREIN, D.O prescribe more brand-name or generic drugs?
FADWA SUMREIN, D.O's prescribing is 62% brand-name and 38% generic drugs by claim count, with $4.0M in brand drug costs.
How many Endocrinology, Diabetes & Metabolism Physician providers are there in the US?
There are 7,852 Endocrinology, Diabetes & Metabolism Physician providers across 54 states in the US. The average Endocrinology, Diabetes & Metabolism Physician provider writes 2,639 Medicare Part D claims per year.
What drugs does FADWA SUMREIN, D.O prescribe most often?
Based on 2023 Medicare Part D data, FADWA SUMREIN, D.O's most frequently prescribed drugs include Ozempic, Trulicity, Jardiance. This reflects Medicare Part D prescriptions only and does not include commercial insurance or other payer types.
Does FADWA SUMREIN, D.O accept Medicare?
FADWA SUMREIN, D.O appears in CMS Medicare data with 6,559 Part D claims and 604 Medicare beneficiaries in 2023. Contact the provider's office directly to confirm current Medicare enrollment and accepted plans.
How can I verify FADWA SUMREIN, D.O's credentials?
FADWA SUMREIN, D.O's NPI is 1043637192 with credentials D.O. You can verify this through the NPPES NPI Registry, check state medical board records, and confirm board certification through the ABMS or AOA.

Data Sources

Provider Directory
CMS National Plan and Provider Enumeration System (NPPES), download.cms.gov/nppes, updated monthly. Contains NPI, specialty, credentials, and practice location.
Specialty Classification
NUCC Health Care Provider Taxonomy (nucc.org), the industry standard for classifying provider specialties in Medicare and Medicaid billing.
Prescribing Data
CMS Medicare Part D Prescriber Public Use File (2023). Includes claims, drug costs, beneficiaries, and opioid prescribing rates.
Quality Performance
CMS Merit-based Incentive Payment System (MIPS) — 2023 performance year.
Limitations
Provider data is self-reported to CMS. Prescribing data reflects Medicare Part D only and does not include commercial insurance, Medicaid, or cash prescriptions. Claims below 11 beneficiaries are suppressed by CMS for privacy.

See our complete data methodology for details on how we collect and process government data.

Data as of April 2026 (NPPES) / 2023 (Medicare Part D). Source: Centers for Medicare & Medicaid Services (CMS).

Disclaimer: Data from CMS NPPES and Medicare Part D. PlainDoctor does not rate or rank providers. Provider information is self-reported and may not be current. Always verify information directly with the provider. About · Methodology